BAUSCH HEALTH COMPANIES INC.

Drug pipeline (144)

Asset	Stage	Revenue	Trials	Status
8-MOP	approved	—	0	—
ACANYA	approved	—	1	approved
ACETAMINOPHEN AND CODEINE PHOSPHATE	approved	—	78	approved
AKNE-MYCIN	approved	—	5	approved
ALBUTEROL SULFATE	approved	—	3	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (194)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT02047604	phase2	completed	2013-12-01	2017-02-23	Bausch Health Americas, Inc.	(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
NCT00679432	phase3	completed	2008-06-01	2010-05-01	Bausch Health Americas, Inc.	(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
NCT00679380	phase3	completed	2008-06-01	2010-02-01	Bausch Health Americas, Inc.	(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis
NCT00801723	phase3	completed	2008-12-01	2011-05-01	Bausch Health Americas, Inc.	(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
NCT01100112	phase3	completed	2010-02-01	2010-07-01	Bausch Health Americas, Inc.	(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets

FDA applications (172)

Application

Approved

Type

Applicant

Products

NDA 216632

2023-10-20

NDA

BAUSCH HEALTH US LLC

NDA 211882

2019-12-18

NDA

BAUSCH HEALTH US LLC

NDA 209354

2019-04-25

NDA

BAUSCH HEALTH AMERICAS INC

NDA 209355

2018-11-06

NDA

BAUSCH HEALTH AMERICAS INC

BLA 761032

2017-02-15

BLA

BAUSCH HEALTH IRELAND, LIMITED